Life Science Intelligence Conference in Barcelona

Adtec Healthcare Ltd will be presenting at the Life Science Intelligence (LSI) Barcelona from 18-22 September 2023. Our Managing Director, Mary, will be showcasing the successes Adtec Healthcare and the SteriPlas have brought to clinical practices dealing with non-healing chronic wounds burdened with biofilm. Mary’s presentation will be held at 10:35 - 10:44 on September 21st and we encourage you to attend and ask your questions to better learn why we remain the leader of high density Cold Plasma medicine.


SteriPlas will be presented at the ISMCS 2023

Congratulations to Mr Thomas Schlöglhofer who has been invited to speak at the International Society for Mechanical Circulatory Support Scientific Congress (ISMCS) on Wednesday 1st November 2023.

 

His presentation, “Cold Atmospheric Plasma for Driveline Infection Treatment” will focus on the benefits of the SteriPlas for LVAD infections.

 

Our medical device has proven efficacy for the treatment of deep LVAD infections with the presence of biofilm. There is growing interest to use our SteriPlas Cold Plasma for LVAD infections due to its quick ability to destroy bacteria protected within biofilm deep within driveline cavity. This is regardless of the type of bacteria or its resistance profile. As LVAD infections can be healed in as quick as 1 week, it provides stability of the independent system and a better quality of life for patients with LVADs.

 

For more information about the SteriPlas, our clinical evidence or a free trial at your hospital contact us at info@adtecplasma


Thomas presents at the ISHLT show

A fantastic presentation delivered by Thomas Schlöglhofer yesterday at the ISHLT - International Society for Heart and Lung Transplantation show. We hope you got the chance to see his presentation and the promising results he has achieved managing LVAD infections with our Cold Plasma SteriPlas medical device. If you are interested to learn more about the SteriPlas and the benefits it can bring to your patients, please contact us at info@adtecplasma.com

 


Cold Plasma Diabetic Foot Ulcer Clinical Trial Published

https://www.woundsinternational.com/journals/issue/667/article-details/efficacy-non-thermal-gas-plasma-treatment-diabetic-foot-ulcers-stalled-subclinical-biofilm-related-wound-infection

Congratulations to Dr Cornelia Wiegand for her published clinical trial paper, “The efficacy of non-thermal gas plasma in the treatment of diabetic foot ulcers stalled by subclinical, biofilm-related wound infection”. This clinical trial paper features the use of our SteriPlas Cold Plasma medical device for the treatment of chronic DFUs infected with biofilm.

 

The parameters of this study were set much higher than a normal study, with there being a much higher standard of care given (3x per week) vs a typical outpatient setting of 1x weekly.

 

We wanted to show that even when chronic diabetic foot ulcers are subjected to more frequent outpatient visits with biopsies and swabs included (something not often collected during standard outpatient visits), SteriPlas Cold Plasma still prevails as the successful treatment method due to its physical mode of action and ability to kill all types of bacteria protected within biofilm.

 


New Wound Management of Driveline Infections with Cold Atmospheric Plasma

 

We’re ecstatic to see Dr Jamila Kremer’s publication, “New Wound Management of Driveline Infections with Cold Atmospheric Plasma” is now live for public viewing. The paper can be viewed here: https://doi.org/10.3390/jcdd9110405.

 

The use of our Adtec cold plasma medical device has greatly benefitted her LVAD infection patients treated at the University Heidelberg Hospital since 2019. The results stipulate a stronger infection management advantage over conventional therapy alone for LVAD infections. This is coupled with the benefit of our cold plasma being safe, painless, contact-free and free from side effects.

Driveline infections are the most prevalent infections and reported in up to 60% of LVAD patient cases. Infection of the LVAD system is the fourth most common cause of death within one year after implantation. Dr Kremer’s publication documents Adtec cold plasma treated patients showed a 100% survival rate.

 

For more information about the benefits of our Cold Plasma medical device, contact us at info@adtecplasma.com


The ISHLT discusses the Cold Plasma Project

We’re ecstatic to see our Adtec SteriPlas continue to raise awareness in the LVAD community. A great interview between the ISHLT and Mr Thomas Schlöglhofer from the Medical University of Vienna discussing the benefits of our cold atmospheric plasma medical device for the treatment of LVAD Infections and their broad study being conducted.

Thomas has been an avid user of our medical device for some time now collecting remarkable results with his LVAD patients, documenting the strong benefits of our medical device including the significant reduction of infection rates coupled with full healing, reduction of readmittance and the stabilisation of LVAD systems all with the added benefit of no side effects.

We look forward to the completion of this study and the publishing of the data which will be discussed at the ISHLT 2023 conference next year. We will also be exhibiting at this conference and excited to meet more people from the LVAD community.

 

https://youtu.be/6-L0sgXLx9o


Characterisation of a Cold Atmospheric Pressure Plasma Torch for Medical Applications

 

We congratulate Dr Adam Bennett on his most recent publication, “Characterisation of a Cold Atmospheric Pressure Plasma Torch for Medical Applications: Demonstration of Device Safety”.

 

The safety and effectiveness of plasma devices are of crucial importance, especially for applications where the plasma is discharged near humans. This study presents the novel design and characterisation of a Cold Atmospheric Plasma torch (SteriPlas), which is used in medical applications. The study shows the characterisation methodology that must be undertaken to show that a plasma device is safe, especially when used in an application on human skin. The emission spectrum discharged from the plasma torch is shown. The UV emitted is measured and the effective irradiance is calculated. The effective irradiance enables the determination of the maximum UV exposure limits, which in this application are shown to be over two hours; however, in some applications may be only seconds. NOx and ozone emissions are also recorded. The NOx levels in this application are shown to be orders of magnitude lower than their safety limits and the ozone emissions are also shown to be safe; however, in some plasma technologies the NOx and ozone levels are orders of magnitude higher than the safe levels.

 

This paper concludes with a discussion of how safety limits vary in different regions around the world and proposes an international standard. It documents the safety of our medical device which further reiterates one of our main strengths where no side effects have been reported.

 

Access to the full paper can be found here: https://www.mdpi.com/2076-3417/11/24/11864


The first cold plasma medical device to treat Scleroderma

 

We congratulate Dr Stephanie Ardnt and Prof. Sigrid Karrer from the University Hospital Regensburg for their recent publication, “The Anti-Fibrotic Effect of Cold Atmospheric Plasma on Localized Scleroderma In Vitro and In Vivo”.

 

This publication features the use of our Adtec SteriPlas and shows strong efficacy for the treatment of Scleroderma, which up to now has not yet been evaluated by CAP. The extensive study documents significantly reduced dermal thickness and collagen deposition as well as a decrease in both alpha smooth muscle actin-positive myofibroblasts and CD68-positive macrophages in the affected skin in comparison to untreated fibrotic tissue. This study provides the first evidence for the successful use of CAP for treating LS and may be the basis for clinical trials including patients with LS.

 

https://doi.org/10.3390/biomedicines9111545


Safe UV and Reactive Species levels only with the Adtec SteriPlas

As a leading medical device company, the crucial balance of safety and clinical efficacy are a top priority. We are always conducting tests to demonstrate the approved safety and reliability of the Adtec SteriPlas but to also learn new ways to improve the use of cold plasma in medicine.

 

Our clinical studies already validate the safety of the Adtec SteriPlas, including its low-level UV and reactive species produced from the cold plasma. These two components are imperative for the physical destruction of bacteria, however, too much of a good thing can also be relatively damaging like that observed with cold plasma jet/pens and battery powered cold plasma devices.

 

Measured across multiple distances, the UV light produced is well below the ICNIRP limit of 30 J/m2 and the reactive species produced are well below the occupational limits set by NIOSH and UK HSE. The Adtec SteriPlas continues to be one of the only cold plasma medical devices that puts patient and user safety first with no reported side effects and promising clinical efficacy from every treatment conducted.

For more information about the Adtec SteriPlas, send us an email at info@adtecplasma.com


Casopis Lecba ran-page-003

Did you see the Adtec SteriPlas featured in the Czech Society for Wound Healing magazine?


Dr Hokynková from the Department of Burns and Plastic Surgery at Brno Hospital in Czech Republic had published a case study in the magazine to document the efficacy of the Adtec SteriPlas after having tested this on a variety of wounds including pressure ulcers and diabetic foot ulcers.

 

The article validates the SteriPlas’ ability to significantly reduce microbial load within the wound which allows the body to regain control and accelerate healing of stalled wounds. This includes wounds that are already contaminated with biofilm and listed for amputations. A change from the conventional therapies already existing on the market, the Adtec SteriPlas has proven to reverse further deterioration of complicated wounds and allow full healing and stability to be achieved.

 

For a translation of the article or to learn more about our efficacy and treatment options, please email us at info@adtecplasma.com